Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy.

Background: Prostate specific antigen (PSA) is an important biomarker to monitor the response to the treatment, but has not been fully utilized as a whole sequence. We used a longitudinal biomarker PSA to discover a new prognostic pattern that predicts castration-resistant prostate cancer (CRPC) aft...

Descripción completa

Detalles Bibliográficos
Publicado en:BMC Medical Informatics & Decision Making Vol. 16; pp. 1 - 10
Autores principales: Yejin Kim, Park, Yong Hyun, Ji Youl Lee, In Young Choi, Hwanjo Yu, Kim, Yejin, Lee, Ji Youl, Choi, In Young, Yu, Hwanjo
Formato: research Journal Article
Publicado: BioMed Central 7/18/2016
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Background: Prostate specific antigen (PSA) is an important biomarker to monitor the response to the treatment, but has not been fully utilized as a whole sequence. We used a longitudinal biomarker PSA to discover a new prognostic pattern that predicts castration-resistant prostate cancer (CRPC) after androgen deprivation therapy.Methods: We transformed the longitudinal PSA into a discrete sequence, used frequent sequential pattern mining to find candidate patterns from the sequences, and selected the most predictive and informative pattern among the candidates.Results: Patients were less likely to be CRPC if, after PSA values reach nadir, the PSA decreases more than 0.048 ng/ml during a month, and the decrease occurs again. This pattern significantly increased the accuracy of predicting CRPC by supplementing information provided by existing PSA patterns such as pretreatment PSA.Conclusions: This result can help clinicians to stratify men by the risk of CRPC and to determine the patient that needs intensive follow-up.